In this episode of Freakonomics Radio, Ezekiel Emanuel discusses the rising popularity of GLP-1 drugs. Originally designed for type 2 diabetes, these medications have proven effective for weight loss and may also benefit heart health and addiction treatment. However, their high price and inconsistent insurance coverage raise important ethical and economic issues about access and fairness. Emanuel explores how different countries handle coverage and calls for a more affordable and comprehensive approach in the U.S., emphasizing the importance of long-term healthcare investment despite immediate cost concerns. He also shares insights on the future of medicine, including the role of AI and the need for better healthcare policies.
